{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:04Z","timestamp":1793924824867,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129267","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:31:32Z","timestamp":1792251092000},"page":"129267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When models diverge: Harmonizing pneumococcal vaccination cost-effectiveness analyses to inform PCV20 and PCV21 use in US adults"],"prefix":"10.1016","volume":"94","author":[{"given":"Kenneth J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"Wateska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muloongo","family":"Simuzingili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elamin H.","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129267_bb0005","series-title":"Summary of three economic analyses on the use of 21-valent pneumococcal conjugate vaccine (PCV21) among adults in the United States","author":"Leidner","year":"2024"},{"issue":"30","key":"10.1016\/j.vaccine.2026.129267_bb0010","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1016\/j.vaccine.2022.04.026","article-title":"Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts","volume":"40","author":"Postma","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129267_bb0015","author":"Leidner"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129267_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129267_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the advisory committee on immunization practices - United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"22","key":"10.1016\/j.vaccine.2026.129267_bb0030","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jama.2023.24766","article-title":"Collaborative modeling to compare different breast Cancer screening strategies: a decision analysis for the US preventive services task force","volume":"331","author":"Trentham-Dietz","year":"2024","journal-title":"JAMA"},{"issue":"1_suppl","key":"10.1016\/j.vaccine.2026.129267_bb0035","doi-asserted-by":"crossref","first-page":"112s","DOI":"10.1177\/0272989X17743244","article-title":"Comparing CISNET breast cancer models using the maximum clinical incidence reduction methodology","volume":"38","author":"van den Broek","year":"2018","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2026.129267_bb0040","series-title":"Comparative study of different weather forecasting models","author":"Medar","year":"2017"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129267_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1175\/WAF-D-21-0102.1","article-title":"Performance of 2020 real-time Atlantic hurricane forecasts from high-resolution global-nested hurricane models: HAFS-globalnest and GFDL T-SHiELD","volume":"37","author":"Hazelton","year":"2022","journal-title":"Weather Forecast"},{"key":"10.1016\/j.vaccine.2026.129267_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127433","article-title":"Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older","volume":"61","author":"Altawalbeh","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129267_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127264","article-title":"Economic evaluation of PCV21 in PCV-na\u00efve adults aged 50\u201364 years in the United States","volume":"59","author":"Yi","year":"2025","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129267_bb0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.amepre.2019.10.022","article-title":"Pneumococcal vaccination in adults aged \u226565 years: cost-effectiveness and health impact in U.S. populations","volume":"58","author":"Wateska","year":"2020","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129267_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-019-1403-9","article-title":"Guidelines for multi-model comparisons of the impact of infectious disease interventions","volume":"17","author":"den Boon","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.129267_bb0070","series-title":"ABCs Bact Facts Interactive Data Dashboard","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"10.1016\/j.vaccine.2026.129267_bb0075","author":"Agency for Healthcare Research and Quality"},{"key":"10.1016\/j.vaccine.2026.129267_bb0080","series-title":"Economic assessment of PCV15 & PCV20","author":"Stoecker","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129267_bb0085","series-title":"Economic assessment of PCV21 in U.S. Adults","author":"Stoecker","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129267_bb0090","series-title":"CPI for all urban consumers (CPI-U): medical care in U.S. city average, all urban consumers, not seasonally adjusted","author":"Bureau of Labor Statistics","year":"2023"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129267_bb0095","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","article-title":"The challenge of transparency and validation in health economic decision modelling: a view from Mount Hood","volume":"37","author":"Kent","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2026.129267_bb0100","series-title":"Summary of three economic models assessing pneumococcal vaccines in US adults","author":"Leidner","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129267_bb0105","series-title":"Overview of three economic analyses of pneumococcal vaccinations at age 65","author":"Leidner","year":"2019"},{"key":"10.1016\/j.vaccine.2026.129267_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.puhe.2025.106022","article-title":"Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations","volume":"249","author":"Smith","year":"2025","journal-title":"Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129267_bb0115","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s40121-026-01364-x","article-title":"Economic evaluation of PCV21 use in populations with increasing serotype 4 invasive pneumococcal disease in the US: an attributable fraction threshold analysis","volume":"15","author":"Yi","year":"2026","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.129267_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127940","article-title":"Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults","volume":"69","author":"Stoecker","year":"2026","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129267_bb0125","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1093\/infdis\/jiaf376","article-title":"Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines","volume":"232","author":"King","year":"2025","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129267_bb0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erv.13.36","article-title":"Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples","volume":"12","author":"Postma","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129267_bb0135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1055\/s-0030-1262859","article-title":"Methoden der gesundheits\u00f6konomischen Evaluation in der Versorgungsforschung","volume":"72","author":"Icks","year":"2010","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.vaccine.2026.129267_bb0140","series-title":"The economic value of adult vaccination in Australia","author":"Cullen","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129267_bb0145","unstructured":"PHARMAC, Te Pataka Whaioranga. Factors for Consideration 2026. https:\/\/www.pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/policies-manuals-and-processes\/factors-for-consideration. Accessed 5\/18\/26."},{"key":"10.1016\/j.vaccine.2026.129267_bb0150","series-title":"Guidelines for the Economic Evaluation of Vaccination Programs in Canada","first-page":"1","author":"National Advisory Committee on Immunization (NACI)","year":"2023"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129267_bb0155","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1377\/hlthaff.24.3.744","article-title":"Development of immunization policy and its implementation in the United Kingdom","volume":"24","author":"Salisbury","year":"2005","journal-title":"Health Aff"},{"issue":"30","key":"10.1016\/j.vaccine.2026.129267_bb0160","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.vaccine.2022.04.050","article-title":"Capturing the value of vaccination within health technology assessment and health economics: literature review and novel conceptual framework","volume":"40","author":"Beck","year":"2022","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:04Z","timestamp":1793922844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"alternative-id":["S0264410X26010765"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129267","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When models diverge: Harmonizing pneumococcal vaccination cost-effectiveness analyses to inform PCV20 and PCV21 use in US adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129267"}}